A kind of albuterol sulfate sustained-release inhalation preparation and its production process

A technology for salbutamol sulfate and inhalation preparations is applied in respiratory diseases, medical preparations with inactive ingredients, and medical preparations containing active ingredients, etc., to achieve the effects of improving heat resistance stability, improving dispersibility, and reducing agglomeration.

Active Publication Date: 2021-04-06
深圳大佛药业股份有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently commercially available albuterol sulfate products are mostly tablets and injections, and salbutamol sulfate sustained-release inhalation preparations are less, so it is imminent to develop a salbutamol sulfate inhalation preparation that can relieve the acute attack of asthma and has a good sustained-release effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of albuterol sulfate sustained-release inhalation preparation and its production process
  • A kind of albuterol sulfate sustained-release inhalation preparation and its production process
  • A kind of albuterol sulfate sustained-release inhalation preparation and its production process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1, a kind of albuterol sulfate sustained-release inhalation preparation

[0039] The salbutamol sulfate sustained-release inhalation preparation includes the following components and parts by mass: 120 parts of salbutamol sulfate complex liquid, 88 parts of liposomes, 1 part of emulsifier, 0.5 part of stabilizer; the liposomes are composed of lecithin , glyceryl behenate and cholesterol are composed of 10:7:2 in mass ratio; the emulsifier is composed of sucrose fatty acid ester and sodium stearoyl lactylate in a mass ratio of 4:1; the stabilizer is composed of oleic acid and half milk Mannan is composed by mass ratio of 8:3.

[0040] Said salbutamol sulfate compound solution is made up of following components and mass parts thereof: 20 parts of salbutamol sulfate, 1 part of polyethylene glycol with molecular weight of 400, 0.2 part of polyvinylpyrrolidone with molecular weight of 58000, oligochitosan with molecular weight of 1000 1 part, 620 parts of water. ...

Embodiment 2

[0051] Embodiment 2, a kind of albuterol sulfate sustained-release inhalation preparation

[0052] The salbutamol sulfate sustained-release inhalation preparation includes the following components and parts by mass: 140 parts of salbutamol sulfate complex liquid, 105 parts of liposomes, 2 parts of emulsifiers, 1.2 parts of stabilizers; the liposomes are composed of lecithin , glyceryl behenate and cholesterol are formed by mass ratio 13:4:1; Described emulsifier is made up of alkyl polyglucoside and sorbitan oleic acid ester by mass ratio 3:2; Described stabilizing agent is made up of oleic acid and The galactomannans are composed at a mass ratio of 12:1.

[0053] Said salbutamol sulfate complex liquid is made up of following components and mass parts thereof: 25 parts of salbutamol sulfate, 2 parts of polyethylene glycols with molecular weight of 400, 0.5 part of polyvinylpyrrolidone with molecular weight of 58000, chitosan oligosaccharide with molecular weight of 1000 3 par...

Embodiment 3

[0064] Embodiment 3, a kind of albuterol sulfate sustained-release inhalation preparation

[0065] The salbutamol sulfate sustained-release inhalation preparation includes the following components and parts by mass: 130 parts of salbutamol sulfate complex solution, 95 parts of liposomes, 1.6 parts of emulsifier, 0.9 parts of stabilizer; the liposomes are composed of lecithin , glyceryl behenate and cholesterol are composed of 12:5:1 by mass ratio; the emulsifier is composed of sucrose fatty acid ester and alkyl polyglucoside by mass ratio of 2:5; the stabilizer is composed of oleic acid and galactose Mannan is composed by mass ratio of 10:3.

[0066] Said salbutamol sulfate compound solution is made up of following components and mass parts thereof: 22 parts of salbutamol sulfate, 1.4 parts of polyethylene glycol with molecular weight of 400, 0.3 part of polyvinylpyrrolidone with molecular weight of 58000, chitosan oligosaccharide with molecular weight of 1000 2 parts, 660 pa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, and in particular relates to a salbutamol sulfate sustained-release inhalation preparation and a production process thereof. The salbutamol sulfate sustained-release inhalation preparation provided by the invention comprises the following components and parts by mass: 120-140 parts of salbutamol sulfate compound solution, 88-105 parts of liposome, 1-2 parts of emulsifier, and 0.5-0.5 parts of stabilizer 1.2 servings. The salbutamol sulfate sustained-release inhalation preparation provided by the invention can relieve the acute attack of asthma and has good sustained-release effect. In addition, the albuterol sulfate sustained-release inhalation preparation provided by the invention also has good storage stability and spray stability.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to a salbutamol sulfate sustained-release inhalation preparation and a production process thereof. Background technique [0002] With the rapid development of the economy, the development of industry is particularly significant, and various diseases caused by environmental pollution problems have attracted more and more attention. Among them, small particles such as PM2.5 and PM10 enter the respiratory tract through human breathing, and the incidence of respiratory diseases is also significantly increased. At present, the research on rapid treatment of respiratory system and even respiratory and lung diseases has become particularly important. The traditional treatment methods for such diseases are mainly oral administration, injection and external application, but the drug takes a long time to exert its effect and poor patient compliance. Inhalation administration has graduall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/72A61K31/137A61K9/127A61K47/10A61K47/12A61K47/26A61K47/32A61K47/36A61P11/06
CPCA61K9/0078A61K9/127A61K31/137A61K47/10A61K47/12A61K47/26A61K47/32A61K47/36A61P11/06
Inventor 杨瑞雄
Owner 深圳大佛药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap